Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Taipei – September 12, 2026 -- HanchorBio Inc. (TWSE: 7827) said the U.S. Food and Drug Administration has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101-EA-001) as "safe to proceed," allowing a Phase 1 patient who showed clinical benefit to continue receiving the investigational drug beyond the parent trial.

South San Francisco, Calif. – September 12, 2026 -- IDEAYA Biosciences and Servier have dosed the first patient in OptimUM-11, a global Phase 3 trial testing darovasertib combined with crizotinib as adjuvant therapy for primary uveal melanoma, targeting a disease segment with no approved systemic treatment options.

London and San Sebastián, Spain – September 12, 2026 -- EpilepsyGTx has partnered with AAV-focused CDMO Viralgen to manufacture EPY201, an investigational gene therapy targeting focal refractory epilepsy (FRE), a condition affecting an estimated 10 million patients worldwide, including 2 million across the US, UK and EU.

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) platform achieved sustained transfusion independence or elimination of vaso-occlusive crises (VOCs) in four new patients from Nigeria, Laos, Malaysia and Pakistan, extending clinical validation beyond the Chinese cohort where five patients previously achieved full transfusion independence.

London – September 9, 2026 -- CD&R has appointed Giovanni Caforio, current Chair of Novartis and former CEO of Bristol Myers Squibb (BMS), as an Operating Advisor to its funds, tasking him with sourcing and evaluating healthcare investment opportunities globally.

Rotterdam – September 12, 2026 -- SkylineDx has completed its transition from third-party distribution to a fully integrated U.S. commercial organization for Merlin CP-GEP, scaling its dedicated sales, marketing and clinical staff from three representatives in early 2025 to more than 25 professionals across key U.S. territories.

Seattle – September 12, 2026 -- Just – Evotec Biologics has initiated a first-in-human Phase 1 clinical trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, developed under a U.S. Department of War contract.

Cleveland – September 12, 2026 -- A research team from Cleveland Clinic, RIKEN and IBM has been named a finalist for the 2026 ACM Gordon Bell Prize after simulating a 12,635-atom protein complex, the largest biologically meaningful molecule ever modeled using quantum computers. The winner will be announced at SC26 in Chicago, running Nov. 15-20, 2026.

Tokyo -- Kaneka Corporation will appeal a September 2, 2026 ruling by the U.S. District Court for the Eastern District of New York that invalidated its U.S. Patent No. 7,829,080 covering reduced coenzyme Q10, known as ubiquinol.